Display Settings:

Format

Send to:

Choose Destination

    J Steroid Biochem Mol Biol. 2008 Feb;108(3-5):203-12. Epub 2007 Sep 14.

    Integration of progesterone receptor action with rapid signaling events in breast cancer models.

    Lange CA.

    University of Minnesota Cancer Center, Department of Medicine, Division of Hematology, Oncology, and Transplant, 420 Delaware Street SE, Minneapolis, MN 55455, USA. Lange047@umn.edu

    Recent discoveries suggest that several protein kinases are rapidly activated in response to ligand binding to cytoplasmic steroid hormone receptors (SRs), including progesterone receptors (PRs). Thus, PRs act as ligand-activated transcription factor "sensors" for growth factor-initiated signaling pathways in hormonally regulated tissues, such as the breast. Induction of rapid signaling upon progestin binding to PR-B provides a means to ensure that receptors and co-regulators are appropriately phosphorylated as part of optimal transcription complexes. Alternatively, PR-B activated kinase cascades provide additional avenues for progestin-regulated gene expression independent of PR nuclear action. Herein, an overview of progesterone/PR and signaling cross-talk in breast cancer models is provided. Kinases are emerging as key mediators of PR action. Cross-talk between SR and membrane-initiated signaling events suggests a mechanism for coordinate regulation of gene subsets by mitogenic stimuli in hormonally responsive normal tissues, and is suspected to contribute to cancer biology.

    PMID: 17964138 [PubMed - indexed for MEDLINE]

    PMCID: 2330263

    Supplemental Content

    Click here to read Click here to read Click here to read Click here to read Click here to read

    Patient drug information

    • Progesterone (Prometrium®)

      Progesterone is used as a part of hormone replacement therapy in women who have passed menopause (the change of life) and have not had a hysterectomy (surgery to remove the uterus). Hormone replacement therapy usually in...